Sign in

or Register now

MyAsthmaCentral.com

See all of our health sites at www.HealthCentral.com
Thursday, November, 12, 2009
  • Font size
Are you an asthma suffer?  Manage your asthma or COPD with great ideas from people like you.Start here.

Advair and Symbicort: “Benefits Outweigh Risk” says an FDA Advisory Committee

James Thompson, MD
James Thompson, MD
Close
James Thompson, MD is How are you doing?
Board Certified Allergist and Internist

I spend most of my time treating patients with asthma and allergic...

James Thompson, MD

Monday, December 15, 2008
View All of James Thompson, MD's Posts

I'm An Adult... Could I have Asthma?

Adults, not just kids, can develop asthma.

Download Guide

Last week, the Food and Drug Administration (FDA) listened to presentations and comments from several members of an expert FDA advisory committee regarding the benefit-to-risk ratio of Long Acting Beta-agonist drugs (LABAs) -- namely Serevent (salmeterol), Foradil (formoterol), Advair (a combination of fluticasone and salmeterol) and Symbicort (a combination of budesonide and formoterol).

 

The FDA advisory panel voted, unanimously, that the benefit of Advair and Symbicort outweighed the risks of adverse effects in adults, but that the risks of Serevent and Foradil -- particularly when used without a anti-inflammatory steroid -- outweighed the benefits for asthmatics.

 

So, what does all of this mean for you?

 

Continue reading "Advair and Symbicort: "Benefits Outweight the Risk" Says an FDA Advisory Comittee.

 

 

 

Get more information on Advair, Symbicort and Long-Acting Beta Agonists here.

  • Font size
  • Bookmark
  • Thank you for your input
  • Save
  • RSS
  • Report Abuse

Ask a Question

Get answers from our experts and community members.

View all questions (671) >